Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in Advanced Cancer Patients With Hepatic and Renal Dysfunction
NCT02567396Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Incidence of toxicity, Recommended phase 2 dose up to 28 days and 1 more. Planned start Jun 2016; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02567396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567396.